Logo image of MDNA.CA

MEDICENNA THERAPEUTICS CORP (MDNA.CA) Stock Fundamental Analysis

TSX:MDNA - Toronto Stock Exchange - CA58490H1073 - Common Stock - Currency: CAD

1.15  -0.05 (-4.17%)

Fundamental Rating

2

We assign a fundamental rating of 2 out of 10 to MDNA. MDNA was compared to 25 industry peers in the Biotechnology industry. MDNA scores quite bad on profitability, while its financial health is fine. Not spectacular, but in line with the averages. MDNA does not seem to be growing, but still is valued expensively.


Dividend Valuation Growth Profitability Health

Quickly go to:

1

1. Profitability

1.1 Basic Checks

In the past year MDNA has reported negative net income.
In the past year MDNA has reported a negative cash flow from operations.
In the past 5 years MDNA always reported negative net income.
MDNA had a negative operating cash flow in each of the past 5 years.
MDNA.CA Yearly Net Income VS EBIT VS OCF VS FCFMDNA.CA Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 -5M -10M -15M -20M -25M

1.2 Ratios

Looking at the Return On Assets, with a value of -81.03%, MDNA is in line with its industry, outperforming 60.00% of the companies in the same industry.
Looking at the Return On Equity, with a value of -133.06%, MDNA is in the better half of the industry, outperforming 75.00% of the companies in the same industry.
Industry RankSector Rank
ROA -81.03%
ROE -133.06%
ROIC N/A
ROA(3y)-85.64%
ROA(5y)-63.93%
ROE(3y)-211%
ROE(5y)-140.25%
ROIC(3y)N/A
ROIC(5y)N/A
MDNA.CA Yearly ROA, ROE, ROICMDNA.CA Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 2024 -100 -200 -300 -400

1.3 Margins

MDNA does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
MDNA.CA Yearly Profit, Operating, Gross MarginsMDNA.CA Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023 2024

More info and screens

5

2. Health

2.1 Basic Checks

Compared to 1 year ago, MDNA has about the same amount of shares outstanding.
The number of shares outstanding for MDNA has been increased compared to 5 years ago.
MDNA has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
MDNA.CA Yearly Shares OutstandingMDNA.CA Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M
MDNA.CA Yearly Total Debt VS Total AssetsMDNA.CA Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 2024 10M 20M 30M 40M

2.2 Solvency

MDNA has an Altman-Z score of -1.42. This is a bad value and indicates that MDNA is not financially healthy and even has some risk of bankruptcy.
The Altman-Z score of MDNA (-1.42) is better than 75.00% of its industry peers.
MDNA has a Debt/Equity ratio of 0.01. This is a healthy value indicating a solid balance between debt and equity.
Looking at the Debt to Equity ratio, with a value of 0.01, MDNA belongs to the top of the industry, outperforming 90.00% of the companies in the same industry.
Industry RankSector Rank
Debt/Equity 0.01
Debt/FCF N/A
Altman-Z -1.42
ROIC/WACCN/A
WACCN/A
MDNA.CA Yearly LT Debt VS Equity VS FCFMDNA.CA Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 20M -20M

2.3 Liquidity

A Current Ratio of 11.40 indicates that MDNA has no problem at all paying its short term obligations.
MDNA's Current ratio of 11.40 is amongst the best of the industry. MDNA outperforms 100.00% of its industry peers.
MDNA has a Quick Ratio of 11.40. This indicates that MDNA is financially healthy and has no problem in meeting its short term obligations.
MDNA has a Quick ratio of 11.40. This is amongst the best in the industry. MDNA outperforms 100.00% of its industry peers.
Industry RankSector Rank
Current Ratio 11.4
Quick Ratio 11.4
MDNA.CA Yearly Current Assets VS Current LiabilitesMDNA.CA Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2023 2024 10M 20M 30M 40M

More info and screens

1

3. Growth

3.1 Past

MDNA shows a strong negative growth in Earnings Per Share. In the last year the EPS decreased by -117.65%.
EPS 1Y (TTM)-117.65%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%0%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

The Earnings Per Share is expected to grow by 13.85% on average over the next years. This is quite good.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y31.06%
EPS Next 2Y10.28%
EPS Next 3Y13.85%
EPS Next 5YN/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
MDNA.CA Yearly Revenue VS EstimatesMDNA.CA Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 20M 40M 60M 80M
MDNA.CA Yearly EPS VS EstimatesMDNA.CA Yearly EPS VS EstimatesYearly EPS VS Estimates 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 -0.1 -0.2 -0.3 -0.4

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

MDNA reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for MDNA. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
MDNA.CA Price Earnings VS Forward Price EarningsMDNA.CA Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 10 20 30

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
MDNA.CA Per share dataMDNA.CA EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 0.2 -0.2

4.3 Compensation for Growth

MDNA's earnings are expected to grow with 13.85% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y10.28%
EPS Next 3Y13.85%

More info and screens

0

5. Dividend

5.1 Amount

MDNA does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

MEDICENNA THERAPEUTICS CORP

TSX:MDNA (2/21/2025, 7:00:00 PM)

1.15

-0.05 (-4.17%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)02-13 2025-02-13/bmo
Earnings (Next)06-25 2025-06-25/amc
Inst Owners6.96%
Inst Owner ChangeN/A
Ins Owners15.14%
Ins Owner ChangeN/A
Market Cap89.95M
Analysts82
Price Target5.74 (399.13%)
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)18.3%
Min EPS beat(2)18.3%
Max EPS beat(2)18.3%
EPS beat(4)3
Avg EPS beat(4)-53.64%
Min EPS beat(4)-256.51%
Max EPS beat(4)18.3%
EPS beat(8)7
Avg EPS beat(8)-5.55%
EPS beat(12)11
Avg EPS beat(12)7.15%
EPS beat(16)11
Avg EPS beat(16)-1.22%
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)31.21%
EPS NQ rev (1m)4.76%
EPS NQ rev (3m)-33.34%
EPS NY rev (1m)-7.35%
EPS NY rev (3m)-2.81%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)-100%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S N/A
P/FCF N/A
P/OCF N/A
P/B 4.49
P/tB 4.5
EV/EBITDA N/A
EPS(TTM)-0.37
EYN/A
EPS(NY)-0.28
Fwd EYN/A
FCF(TTM)-0.22
FCFYN/A
OCF(TTM)-0.21
OCFYN/A
SpS0
BVpS0.26
TBVpS0.26
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -81.03%
ROE -133.06%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-85.64%
ROA(5y)-63.93%
ROE(3y)-211%
ROE(5y)-140.25%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score4
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity 0.01
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr N/A
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 11.4
Quick Ratio 11.4
Altman-Z -1.42
F-Score4
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-117.65%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%0%
EPS Next Y31.06%
EPS Next 2Y10.28%
EPS Next 3Y13.85%
EPS Next 5YN/A
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y-7.03%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y-2.83%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-2.63%
OCF growth 3YN/A
OCF growth 5YN/A